ストックスクリーナーアプリを入手
34.78
0.66%
-0.23
アフターアワーズ：
34.78
Lb Pharmaceuticals Inc (LBRX) 最新ニュース
LB Pharmaceuticals Inc (LBRX) Balance Sheet - TradingKey
LB Pharmaceuticals Inc (LBRX) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
LBRX|LB Pharmaceuticals Inc|Price:35.010|Chg%:+0.390 - TradingKey
LB Pharmaceuticals Inc (LBRX) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
LB Pharmaceuticals Inc (LBRX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
LB Pharmaceuticals Inc (LBRX) Institutional Confidence - TradingKey
LB Pharmaceuticals Inc (LBRX) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
H.C. Wainwright Maintains LB Pharmaceuticals(LBRX.US) With Buy Rating, Maintains Target Price $45 - Moomoo
LB Pharmaceuticals Inc $LBRX is Spruce Street Capital LP's 3rd Largest Position - MarketBeat
Enterprise value to revenue forward of LB Pharmaceuticals Inc – BOATS:LBRX - TradingView
H.C. Wainwright reiterates Buy on LB Pharmaceuticals stock By Investing.com - Investing.com Nigeria
H.C. Wainwright reiterates Buy on LB Pharmaceuticals stock - Investing.com
LB Pharmaceuticals: Buy Rating Reaffirmed on LB-102 Clinical Momentum and Regulatory Progress; $45 Price Target Maintained - TipRanks
LB Pharmaceuticals Inc (LBRX) Stock Price, News, Quote & History - Yahoo! Finance Canada
Analysts Offer Insights on NA Companies: Exodus Movement, Inc. Class A (EXOD) and LB Pharmaceuticals, Inc. (LBRX) - The Globe and Mail
LB Pharmaceuticals Inc (LBRX) stock price, news, quote and history - Yahoo Finance Singapore
LB Pharmaceuticals (NASDAQ:LBRX) Reaches New 1-Year HighTime to Buy? - MarketBeat
LB Pharmaceuticals accelerates Phase 3 schizophrenia trial timeline - TipRanks
LB Pharmaceuticals accelerates schizophrenia trial timeline By Investing.com - Investing.com South Africa
LB Pharmaceuticals accelerates schizophrenia trial timeline - Investing.com
LB Pharmaceuticals Announces Accelerated Timing of Topline Results from the Phase 3 NOVA-2 Trial of LB-102 in Schizophrenia - The Manila Times
LB Pharmaceuticals Expects Results From 460-Patient Trial in 1H 2027 - Stock Titan
LB Pharmaceuticals (NASDAQ:LBRX) Upgraded by BMO Capital Markets to Strong-Buy Rating - MarketBeat
JPMorgan Chase & Co. Increases Stake in LB Pharmaceuticals Inc. - GuruFocus
Jennison Associates LLC Sells 283,636 Shares of LB Pharmaceuticals Inc $LBRX - MarketBeat
Enterprise value to EBITDA forward of LB Pharmaceuticals Inc – BOATS:LBRX - TradingView
LB PHARMACEUTICALS INC : BMO INITIATES COVERAGE WITH OUTPERFORM RATING; TARGET PRICE $46 - Bitget
LBRX Initiated Coverage by BMO Capital -- Rated Outperform at $4 - GuruFocus
Price to book forward of LB Pharmaceuticals Inc – NASDAQ:LBRX - TradingView
BMO initiates LB Pharmaceuticals stock at Outperform on drug data By Investing.com - Investing.com South Africa
BMO initiates LB Pharmaceuticals stock at Outperform on drug data - Investing.com
LB Pharmaceuticals Inc (LBRX) Gains 2.68% as Shares Approach Key Resistance at $32.98Volatility Smile - dars.gov.et
Heather Turner: LB Pharma's Schizophrenia Drug Could Go from One Trial to Approval - finance.biggo.com
LB Pharmaceuticals Inc (LBRX) Holds Near $32 as Biotech Sector Shows Mixed SignalsADD Alert - dars.gov.et
LB Pharmaceuticals Inc (NASDAQ:LBRX) Receives Average Recommendation of "Moderate Buy" from Brokerages - MarketBeat
LBRX Q1 2026 Earnings: Narrowed Loss Beats Expectations Amid Pipeline ProgressFinancial Summary - DonanımHaber
LB Pharmaceuticals Inc (LBRX) Slides 2.34% as Technical Support Levels Come into FocusWyckoff Spring - DonanımHaber
LB Pharmaceuticals grants stock options to new SVP under Nasdaq inducement rule - Pluang
LB Pharmaceuticals Grants Inducement Equity Award to New Senior Vice President of Clinical Operations - Quiver Quantitative
LB Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4) - marketscreener.com
Press Release: LB Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4) - Moomoo
LB Pharmaceuticals Inc (LBRX) Edges Higher, Testing Key Resistance ZoneUp Down Ratio - DonanımHaber
LB Pharmaceuticals Inc (LBRX) Gains 2.63% on Above-Average Volume, Tests Key Resistance at $36Call Wall - dars.gov.et
Wolfe Research Initiates LB Pharmaceuticals(LBRX.US) With Buy Rating, Announces Target Price $45 - Moomoo
LBRX Initiated Coverage by Wolfe Research -- Rating Set to Outpe - GuruFocus
LB Pharmaceuticals Initiated at Outperform by Wolfe Research - Moomoo
Wolfe Research initiates LB Pharmaceuticals stock with outperform rating By Investing.com - Investing.com South Africa
Wolfe Research initiates LB Pharmaceuticals stock with outperform rating - Investing.com
LB Pharmaceuticals Inc (LBRX) Gains 4.83% as Stock Approaches Resistance at $35.10Early Entry Signals - dars.gov.et
LBRX Q1 2026 Earnings: EPS Beat Driven by Cost Control Amid Pre-Revenue StageShort-Term Outlook - dars.gov.et
LBRXLB Pharmaceuticals Inc Dividends - Finviz
LB Pharmaceuticals Inc. (LBRX) Maintains Buy Rating as Analyst Highlights LB-102 Potential - Yahoo Finance
5 Best Up and Coming Pharmaceutical Stocks to Buy Now - Insider Monkey
1.97%
0.83%
大文字化:
|
ボリューム (24 時間):